Hematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousGraft vs Leukemia EffectPeripheral Blood Stem Cell TransplantationTransplantation ChimeraTissue DonorsTreatment OutcomeMyeloablative AgonistsGraft SurvivalBone Marrow TransplantationHistocompatibilityBusulfanGraft vs Tumor EffectRetrospective StudiesChimerismRecurrenceWhole-Body IrradiationHistocompatibility TestingLeukemiaStem CellsVidarabineAllograftsHematologic DiseasesCord Blood Stem Cell TransplantationMyelodysplastic SyndromesLeukemia, Myeloid, AcuteSiblingsLymphocyte TransfusionHLA AntigensImmunosuppressive AgentsRemission InductionHepatic Veno-Occlusive DiseaseSurvival RatePrecursor Cell Lymphoblastic Leukemia-LymphomaCytomegalovirus InfectionsTime FactorsSurvival AnalysisAcute DiseaseTransplantation ImmunologyCombined Modality TherapyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemic InfiltrationDisease-Free SurvivalTransplantation, IsogeneicAnemia, AplasticCystitisT-LymphocytesFollow-Up StudiesMinor Histocompatibility AntigensOpportunistic InfectionsLymphocyte DepletionHematopoiesisHematopoietic Stem Cell MobilizationMultiple MyelomaSevere Combined ImmunodeficiencyFlow CytometryNeoplasm, ResidualSalvage TherapyLymphoproliferative DisordersAntilymphocyte SerumLiver TransplantationAntigens, CD34CyclophosphamideRisk FactorsCytomegalovirusBronchiolitis ObliteransBone Marrow CellsMice, Inbred C57BLImmunocompromised HostBlood Group IncompatibilityPhotopheresisPrognosisMycosesImmunosuppressionFatal OutcomeCell DifferentiationLeukemia, MyeloidAntineoplastic Combined Chemotherapy ProtocolsSurvivorsPostoperative ComplicationsMesenchymal Stem Cell TransplantationPrimary MyelofibrosisGanciclovirCell TransplantationFetal BloodIncidenceProspective StudiesUnrelated DonorsKidney TransplantationChronic DiseaseCell LineageIsoantigensCytarabineCyclosporine